BNC Korea Co., Ltd. (256840.KQ)
- Previous Close
4,150.00 - Open
4,185.00 - Bid 4,155.00 x --
- Ask 4,160.00 x --
- Day's Range
4,140.00 - 4,220.00 - 52 Week Range
3,475.00 - 7,200.00 - Volume
143,163 - Avg. Volume
253,369 - Market Cap (intraday)
281.157B - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj., temporary reduce glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity; Juvegel, temporary reduce nasolabial folds in adults; Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia; HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration. It also provides Hibarry, a bio-absorbable gel and solution mixture used to prevent adhesion of the spinal cord post-surgery; GENTA Q, a white collagen sponge, which is used to protect deep cavity wounds such as surgical sites from contamination; and care, beauty face, repair hydrogen masks, mild cleansing foams, and brightening peeling gels. The company also exports its products to 45 countries. BNC Korea Co., Ltd. was founded in 2007 and is headquartered in Daegu, South Korea.
www.bnckorea.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 256840.KQ
View MorePerformance Overview: 256840.KQ
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 256840.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 256840.KQ
View MoreValuation Measures
Market Cap
281.84B
Enterprise Value
202.54B
Trailing P/E
20.96
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.13
Price/Book (mrq)
1.23
Enterprise Value/Revenue
2.27
Enterprise Value/EBITDA
8.02
Financial Highlights
Profitability and Income Statement
Profit Margin
14.91%
Return on Assets (ttm)
2.66%
Return on Equity (ttm)
5.89%
Revenue (ttm)
89.23B
Net Income Avi to Common (ttm)
13.31B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
93.84B
Total Debt/Equity (mrq)
6.15%
Levered Free Cash Flow (ttm)
-5.84B